Newswise — BALTIMORE – May 21, 2014. Researchers at the University of Maryland School of Medicine have identified a mutation in a fat-storage gene that appears to increase the risk for type 2 diabetes and other metabolic disorders, according to a study published online today in the New England Journal of Medicine.
The researchers discovered the mutation in the hormone-sensitive lipase (HSL) gene by studying the DNA of more than 2,700 people in the Old Order Amish community in Lancaster County, Pa. HSL is a key enzyme involved in breaking down stored fat (triglycerides) into fatty acids, thereby releasing energy for use by other cells.
“We found that Amish people with this mutation have defects in fat storage, increased fat in the liver, high triglycerides, low "good" (HDL) cholesterol, insulin resistance and increased risk of developing type 2 diabetes,” says the study’s senior author, Coleen M. Damcott, Ph.D., an assistant professor of medicine in the Division of Endocrinology, Diabetes and Nutrition and member of the Program for Personalized and Genomic Medicine at the University of Maryland School of Medicine.
In this study, 5.1 percent of the Old Order Amish study participants had at least one copy of the mutation. Four people had two copies of the mutation and consequently produced no HSL enzyme, Dr. Damcott says. The mutation is less common in non-Amish Caucasians of European descent (0.2%), thus the higher prevalence of the mutation in the Amish makes it possible to characterize its full range of effects.
“Future studies of this gene will allow us to look more closely at the effects of its deficiency on human metabolism to better understand the function of the HSL protein and its impact on fat and glucose metabolism,” Dr. Damcott says. “These studies will also examine the potential of using HSL as a drug target for treating type 2 diabetes and related complications.”
She notes that type 2 diabetes is a complex disease whose susceptibility is often determined by interactions between genetics and lifestyle factors, such as overeating and physical inactivity. Susceptibility genes for diabetes may be involved in several different metabolic pathways in the body, including storage and release of fat for energy.
“Discovery of this mutation adds to the growing list of insights gained from genomic studies that can be used to develop new treatments and customize existing treatments for type 2 diabetes and related metabolic disorders,” Dr. Damcott says.
E. Albert Reece, M.D., Ph.D., M.B.A., vice president for medical affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and dean of the University of Maryland School of Medicine, says, “This discovery offers intriguing new evidence of how genetics may play a role in how people develop type 2 diabetes and provides a possible target for medical intervention. Through our Program for Personalized and Genomic Medicine, we are always striving to devise effective therapies to fit an individual’s genetic make-up.”
Study co-author Alan R. Shuldiner, M.D., the John L. Whitehurst Endowed Professor of Medicine, associate dean for personalized medicine and director of the Program for Personalized and Genomic Medicine, and his colleagues at the University of Maryland School of Medicine have previously identified a number of susceptibility genes for diabetes as well as for obesity, high blood pressure and other complex diseases. In 2008, they discovered a novel gene mutation among the Old Order Amish population that significantly reduces the level of triglycerides in the blood and appears to help prevent cardiovascular disease. In 2010, they discovered a common gene variant that predicts efficacy of the common anti-platelet medication, clopidogrel (Plavix®).
Dr. Shuldiner’s team has been conducting genetic research with the Old Order Amish in Pennsylvania since the early 1990s.
The Old Order Amish are ideal for genetic studies because they are a genetically homogenous population tracing their ancestry back 14 generations to a small group that came to Pennsylvania from Europe in the mid-1700s.
This study was supported by grants from the National Institutes of Health, the American Heart Association, the University of Maryland Multidisciplinary Clinical Career Development Program, the Mid-Atlantic Nutrition and Obesity Research Center, the Baltimore Diabetes Research Center, the American Diabetes Association, the U.S. Department of Agriculture National Institute of Food and Agriculture, and the Geriatric Research Education and Clinical Center, Baltimore Veterans Affairs (VA) Medical Center.
About the University of Maryland School of Medicine
Established in 1807, the University of Maryland School of Medicine is the first public medical school in the United States, and the first to institute a residency training program. The School of Medicine was the founding school of the University of Maryland and today is an integral part of the 11-campus University System of Maryland. On the University of Maryland's Baltimore campus, the School of Medicine serves as the anchor for a large academic health center which aims to provide the best medical education, conduct the most innovative biomedical research and provide the best patient care and community service to Maryland and beyond. www.medschool.umaryland.edu.
The school’s Program for Personalized and Genomic Medicine Program was established in April 2011 to help facilitate the pace of discovery in personalized and genomic medicine; to accelerate the translation of these new discoveries to improve patient care; and to enhance the training and education of future generations of physicians and scientists. The program is funded jointly by the School of Medicine and University of Maryland Medical Center. #####
Jessica S. Albert, Ph.D., Laura M. Yerges-Armstrong, Ph.D.,Richard B. Horenstein, M.D., Toni I. Pollin, Ph.D., Urmila T. Sreenivasan, M.S., Sumbul Chai, M.S., William S. Blaner, Ph.D., Soren Snitker, M.D., Ph.D., Jeffrey R. O’Connell, Ph.D., Da-Wei Gong, Ph.D., Richard J. Breyer III, M.D., Alice S. Ryan, Ph.D., John C. McLenithan, Ph.D., Alan R. Shuldiner, M.D.,Carole Sztalryd, Ph.D., and Coleen M. Damcott, Ph.D.
MEDIA CONTACTRegister for reporter access to contact details
New England Journal of Medicine, May 21, 2104